Transplantation proceedings · 2013
Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lopez-Meseguer M, Berastegui C, Monforte V, Bravo C, Domingo E, Roman A
Аннотация
BACKGROUND: Accepted treatment for severe pulmonary arterial hypertension (PAH) includes intravenous epoprostenol and lung transplantation (LT). Inhaled iloprost plus oral sildenafil (Ilo-Sil) is an alternative strategy that may also delay the need for LT.
PATIENTS AND METHODS: This was a long-term descriptive study in eight patients with PAH functional class (FC) IV with right heart failure, four of them potential candidates for LT, who were treated with Ilo-Sil as an alternative to epoprostenol.
RESULTS: At the start of the study, patients (seven women; mean age, 43.8 [range, 34-66] years) were in FC IV and unable to perform the 6-minute walk test. Mean cardiac index was 1.9 (range, 1.4-2.1) L/min/m(2). Treatment with Ilo-Sil provoked a rapid and sustained improvement; mean walking distance at 3 months was 322 ± 90 m and no patient remained in FC IV. Survival at 1 and 5 years was 100% and 75%, respectively. Of the four potential LT candidates, one underwent transplantation after 6.8 years and one died after 1.2 years.
CONCLUSIONS: These results suggest that therapy with Ilo-Sil represents an acceptable alternative in patients with severe and unstable PAH.
PATIENTS AND METHODS: This was a long-term descriptive study in eight patients with PAH functional class (FC) IV with right heart failure, four of them potential candidates for LT, who were treated with Ilo-Sil as an alternative to epoprostenol.
RESULTS: At the start of the study, patients (seven women; mean age, 43.8 [range, 34-66] years) were in FC IV and unable to perform the 6-minute walk test. Mean cardiac index was 1.9 (range, 1.4-2.1) L/min/m(2). Treatment with Ilo-Sil provoked a rapid and sustained improvement; mean walking distance at 3 months was 322 ± 90 m and no patient remained in FC IV. Survival at 1 and 5 years was 100% and 75%, respectively. Of the four potential LT candidates, one underwent transplantation after 6.8 years and one died after 1.2 years.
CONCLUSIONS: These results suggest that therapy with Ilo-Sil represents an acceptable alternative in patients with severe and unstable PAH.
Предметные рубрики MeSH
Administration, InhalationAdministration, OralAdultAgedAntihypertensive AgentsArterial PressureDrug Therapy, CombinationExercise ToleranceFamilial Primary Pulmonary HypertensionFemaleHumansHypertension, PulmonaryIloprostLongitudinal StudiesLung TransplantationMaleMiddle AgedPhosphodiesterase 5 InhibitorsPiperazinesPulmonary ArteryPurinesRecovery of FunctionSeverity of Illness IndexSildenafil CitrateSulfonesTime FactorsTime-to-TreatmentTreatment OutcomeVasodilator Agents